2024
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original Research
2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseDiabetes Mellitus, Type 2GlucoseHumansIncretinsInsulinInsulin ResistanceObesityConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroupGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2023, 189: k19-k24. PMID: 37952170, DOI: 10.1093/ejendo/lvad147.Peer-Reviewed Original ResearchConceptsClassical congenital adrenal hyperplasiaClassical CAHCongenital adrenal hyperplasiaContinuous glucose monitoringLower cortisol concentrationsGlucose patternsAdrenal hyperplasiaCortisol concentrationsGlucose monitoringFludrocortisone replacement therapySensor glucose valuesHydrocortisone doseAcute illnessAsymptomatic hypoglycemiaWhole cohortNighttime hypoglycemiaReplacement therapyPercentage of timeObservational studyGlucose profilesGlycemic patternsSerial measuresGlucose valuesDaily cortisolHypoglycemiaQuantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2023, 66: 2189-2199. PMID: 37712956, PMCID: PMC10627950, DOI: 10.1007/s00125-023-06011-5.Peer-Reviewed Original ResearchConceptsType 1 diabetesBeta-cell functionInsulin secretionFunctional beta-cell massEarly pre-symptomatic stagesCell functionPre-symptomatic phaseBeta-cell massDisease-modifying interventionsPre-symptomatic stageContinuous glucose monitoringIslet autoimmunityInsulin sensitivityDisease progressionGlucose profilesInvasive measuresPreclinical stageMetabolic testsProgressive lossDiabetesMetabolic changesGlucose monitoringAvailable testsMeasurable changesOGTTSumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Golubic R, Ismail M, Josipovic M, Kennet J, Galderisi A, Evans M. Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes Obesity And Metabolism 2023, 25: 3059-3063. PMID: 37312648, DOI: 10.1111/dom.15176.Peer-Reviewed Original ResearchConceptsPlacebo-controlled cross-over trialIntravenous glucose tolerance testGlucose tolerance testCross-over trialGlucose effectivenessTolerance testInsulin sensitivityInsulin secretionHyperinsulinaemic euglycaemic clampControl blood glucoseGlucoregulatory roleOverweight adultsOverweight humansEuglycaemic clampInsulin levelsGlucose excursionsBlood glucoseReceptor agonistMouse modelGlucose homeostasisSumatriptanPlaceboSecretionTrialsHumansScreening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis
Weiss L, Reix P, Mosnier-Pudar H, Ronsin O, Beltrand J, Reynaud Q, Mely L, Burgel P, Stremler N, Rakotoarisoa L, Galderisi A, Perge K, Bendelac N, Abely M, Kessler L. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis. Diabetes & Metabolism 2023, 49: 101444. PMID: 37030530, DOI: 10.1016/j.diabet.2023.101444.Peer-Reviewed Original ResearchConceptsGlucose tolerance abnormalitiesCystic fibrosis-related diabetesTolerance abnormalitiesCystic fibrosisAnnual oral glucose tolerance testOral glucose tolerance testGlucose tolerance testLong asymptomatic periodStage of diabetesNew comorbiditiesAsymptomatic periodClinical profileTolerance testNew diagnostic toolsPathophysiological knowledgeDiabetesNutritional outcomesPatientsFibrosisAbnormalitiesScreening strategyLife expectancyDiagnostic toolScreening methodComorbiditiesA New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes
Schiavon M, Galderisi A, Basu A, Kudva Y, Cengiz E, Man C. A New Index of Insulin Sensitivity from Glucose Sensor and Insulin Pump Data: In Silico and In Vivo Validation in Youths with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 270-278. PMID: 36648253, PMCID: PMC10066780, DOI: 10.1089/dia.2022.0397.Peer-Reviewed Original ResearchObstructive sleep apnea (OSA) is associated with the impairment of beta-cell response to glucose in children and adolescents with obesity
Umano G, Galderisi A, Aiello F, Martino M, Camponesco O, Di Sessa A, Marzuillo P, Alfonso P, Miraglia del Giudice E. Obstructive sleep apnea (OSA) is associated with the impairment of beta-cell response to glucose in children and adolescents with obesity. International Journal Of Obesity 2023, 47: 257-262. PMID: 36670156, PMCID: PMC10113157, DOI: 10.1038/s41366-023-01257-w.Peer-Reviewed Original ResearchConceptsMild obstructive sleep apneaObstructive sleep apneaOral glucose tolerance testSevere obstructive sleep apneaInsulin secretionSleep apneaPlasma glucoseCardio-respiratory polygraphyTotal insulin secretionApnea-hypopnea indexOxygen desaturation indexBeta-cell responseGlucose tolerance testBeta-cell functionDynamic insulin secretionSpearman correlation testOral minimal modelOGTT studyReleasable insulinOSA severityDesaturation indexPediatric clinicTolerance testInsulin sensitivityLow prevalence
2022
β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT
Galderisi A, Evans-Molina C, Martino M, Caprio S, Cobelli C, Moran A. β-Cell Function and Insulin Sensitivity in Youth With Early Type 1 Diabetes From a 2-Hour 7-Sample OGTT. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1376-1386. PMID: 36546354, PMCID: PMC10188312, DOI: 10.1210/clinem/dgac740.Peer-Reviewed Original ResearchGlucose variability increases during minimally invasive procedures in very preterm infants
Galderisi A, Res G, Guiducci S, Savio F, Brigadoi S, Forlani L, Mastrandrea B, Moschino L, Lolli E, Priante E, Trevisanuto D, Baraldi E. Glucose variability increases during minimally invasive procedures in very preterm infants. European Journal Of Pediatrics 2022, 182: 89-94. PMID: 36201017, PMCID: PMC9829573, DOI: 10.1007/s00431-022-04641-2.Peer-Reviewed Original ResearchConceptsVery preterm infantsContinuous glucose monitoringPreterm infantsGlucose variabilityNeonatal stressNappy changeInvasive proceduresMedian glucoseGlucose monitoringNon-invasive procedurePrimary outcomeAbsence of changesHeel prickMean glucoseNeonatal proceduresCare proceduresDay 2InfantsParental presenceGlucose variationCGM dataGlucoseSDNeonatesPrickMechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach
Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseGlucoseGlucose IntoleranceHumansInsulinInsulin ResistanceObesityConceptsOral glucose tolerance testΒ-cell functionΒ-cell glucose sensitivityInsulin sensitivityGenetic risk profileMultiple oral glucose tolerance testsDifferent genetic risk profilesRisk profileMin oral glucose tolerance testLatent class trajectory analysisGlucose tolerance testImpaired insulin sensitivityPlasma glucose responseGlucose sensitivityClass 3Model-predicted probabilityClass 1Tolerance testProgressive impairmentMultiethnic cohortGlucose responseLongitudinal changesObesityTransient reductionInsulin kineticsSGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretionA low n‐6 to n‐3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth
Tricò D, Galderisi A, Van Name MA, Caprio S, Samuels S, Li Z, Galuppo BT, Savoye M, Mari A, Feldstein AE, Santoro N. A low n‐6 to n‐3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth. Diabetes Obesity And Metabolism 2022, 24: 1267-1276. PMID: 35297549, PMCID: PMC9177628, DOI: 10.1111/dom.14695.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell glucose sensitivityInsulin clearanceΒ-cell functionObese youthInsulin secretionRatio dietGlucose-dependent insulin secretionAbdominal magnetic resonance imagingWhole-body insulin sensitivityImpaired insulin clearancePostload insulin levelsWorse metabolic profileGlucose tolerance testHepatic fat contentDietary-induced changesGlucose sensitivityMagnetic resonance imagingInsulin levelsHepatic fatInsulin resistancePlasma insulinTolerance testInsulin sensitivityC-peptideLack of Evidence for a Causal Role of Hyperinsulinemia in the Progression of Obesity in Children and Adolescents: A Longitudinal Study.
Halloun R, Galderisi A, Caprio S, Weiss R. Lack of Evidence for a Causal Role of Hyperinsulinemia in the Progression of Obesity in Children and Adolescents: A Longitudinal Study. Diabetes Care 2022, 45: 1400-1407. PMID: 35235641, PMCID: PMC9210872, DOI: 10.2337/dc21-2210.Peer-Reviewed Original ResearchConceptsDegree of obesityOral glucose tolerance testCarbohydrate-insulin modelLower postprandial glucosePostprandial glucoseInsulin secretionMultivariate analysisPostprandial glucose levelsPediatric obesity clinicProgression of obesityGlucose tolerance testCurve of insulinDevelopment of obesityGreater insulin secretionGreater increaseLack of evidenceInsulinogenic indexObesity clinicLower BMIObesity managementTolerance testGlucose levelsPeak insulinHyperinsulinemiaObesityIntraperitoneal Insulin Delivery: Evidence of a Physiological Route for Artificial Pancreas From Compartmental Modeling
Presti J, Galderisi A, Doyle F, Zisser H, Dassau E, Renard E, Toffanin C, Cobelli C. Intraperitoneal Insulin Delivery: Evidence of a Physiological Route for Artificial Pancreas From Compartmental Modeling. Journal Of Diabetes Science And Technology 2022, 17: 751-756. PMID: 35144503, PMCID: PMC10210098, DOI: 10.1177/19322968221076559.Peer-Reviewed Original ResearchConceptsInsulin deliveryClosed-loop insulin deliveryInsulin kineticsIntraperitoneal insulin deliveryPeripheral hyperinsulinemiaGlycemic controlSubcutaneous routePeritoneal compartmentModel predictive controllerPhysiological routeArtificial pancreasCompartmental modelingDeliveryUVA/Padova T1D simulatorCompartmental modelProportional integral derivative (PID) controllerHyperinsulinemia
2021
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Trevisanuto D, Russo C, Hall R, Bruschettini M. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. 2021, 2021: cd013309. PMID: 34931697, PMCID: PMC8690212, DOI: 10.1002/14651858.cd013309.pub3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRisk of hypoglycaemiaUse of CGMContinuous glucose monitoringPreterm infantsIntermittent modalitiesRisk ratioEffects of CGMLong-term neurodevelopmental impairmentGlucose monitoringEfficacy of CGMCare Group (EPOC) criteriaPreterm infants 1Cochrane Effective PracticePrevention of morbidityClinical trials databasesLong-term outcomesConfidence intervalsPreterm infant mortalitySafety of CGMImprecision of estimatesFixed-effects modelAdverse neurodevelopmentGRADE approachNeurodevelopmental outcomesDATA COLLECTION
2020
Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants
Galderisi A, Bruschettini M, Russo C, Hall R, Trevisanuto D. Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants. 2020, 12: cd013309. PMID: 33348448, PMCID: PMC8092644, DOI: 10.1002/14651858.cd013309.pub2.Peer-Reviewed Original ResearchConceptsPreterm infantsContinuous glucose monitoringGlycemic measuresRisk ratioIntermittent modalitiesLong-term neurodevelopmental impairmentGlucose monitoringCare Group (EPOC) criteriaCochrane Central RegisterCochrane Effective PracticePrevention of morbidityQuasi-randomized trialStandard search strategyClinical trials databasesLong-term outcomesPreterm infant mortalityAllied Health LiteratureUse of CGMImprecision of estimatesFixed-effects modelCochrane NeonatalAdverse neurodevelopmentCentral RegisterGRADE approachControlled TrialsEffect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi A, Cohen N, Calhoun P, Kraemer K, Breton M, Weinzimer S, Cengiz E. Effect of Afrezza on Glucose Dynamics During HCL Treatment. Diabetes Care 2020, 43: 2146-2152. PMID: 32661108, PMCID: PMC7440894, DOI: 10.2337/dc20-0091.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, InhalationAdolescentAdultBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugEquipment and SuppliesFemaleGlycemic ControlHumansHypoglycemic AgentsInsulin Infusion SystemsInsulin, Regular, HumanMaleMealsPostprandial PeriodYoung AdultConceptsControl armPremeal bolusesPostprandial plasma glucose levelsPostprandial blood glucose controlPrimary efficacy outcomeRapid-acting insulinBlood glucose controlPlasma glucose levelsType 1 diabetesLater time pointsSequential mealsEfficacy outcomesPPG levelsSecondary outcomesGlycemic excursionsMeal studyGlucose controlSubcutaneous routeInsulin delivery systemsGlucose levelsGlucose metricsHigh doseStudy daysInsulin absorptionInsulin bolus
2019
Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions
Sherr J, Buckingham BA, Forlenza G, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett L, Layne JE, Ly TT. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technology & Therapeutics 2019, 22: 174-184. PMID: 31596130, PMCID: PMC7047109, DOI: 10.1089/dia.2019.0286.Peer-Reviewed Original ResearchConceptsDaily physical activityPhysical activityFree-living conditionsPercentage timeMultiple daily injectionsType 1 diabetesRespective age groupsCohort of participantsHybrid closed-loop systemPrimary endpointDaily injectionsEligible participantsClosed-loop studiesPercentage of timeTherapy phaseInvestigational deviceNights of useAge groupsSensor glucoseType 1Home settingDlSignificant decreaseUsual routineAdultsLower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β-Cell Function Over Time
Galderisi A, Polidori D, Weiss R, Giannini C, Pierpont B, Tricò D, Caprio S. Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β-Cell Function Over Time. Diabetes 2019, 68: 2074-2084. PMID: 31399433, PMCID: PMC6804624, DOI: 10.2337/db19-0120.Peer-Reviewed Original Research